Treatment of cardiopulmonary disorders

US12138256B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Eva Maria Becker-Pelster · Wuppertal, DE
• Hanna Tinel · Wuppertal, DE
• Michael Hahn · Langenfeld, DE
• Dieter Lang · Velbert, DE
• Gerrit Weimann · Moitzfeld, DE
• Johannes NAGELSCHMITZ · Wuppertal, DE
• Lisa DIETZ · Wuppertal, DE
• Soundos SALEH · Wuppertal, DE
• David Kendall Jung · Durham, US
• Ildiko Terebesi · Berlin, DE
• Tobias MUNDRY · Berlin, DE
• Annett Richter · Berlin, DE
• Britta Olenik · Bottrop, DE
• Birgit Keil · Düsseldorf, DE
• Bernd RÖSLER · Wuppertal, DE
• Peter Fey · Wuppertal, DE
• Heiko Schirmer · Solingen, DE
• Guido Becker · Krefeld, DE
• Clemens BOTHE · Leverkusen, DE
• Helene FABER · Dormagen, DE
• Julian EGGER · Remscheid, DE
• Mark PARRY · Terling, GB
• David WARD · Royal Tunbridge Wells, GB
• Cecile VITRE · Pidley, GB

Key dates

• Filing date: Nov 10, 2023
• Grant date: Nov 12, 2024
• Expiry date: Nov 10, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4′-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension with idiopathic interstitial pneumonia (PH-IIP), characterized in that an inhalative dosage form comprising 240 to 4000 μg, pre…